Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MK-1084 alone and in combinations for KRAS G12C-mutant advanced solid tumors
jRCT2041220034Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of calderasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (6 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
calderasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2041220034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220034.